Conditions: IDH1 Gene Mutation; IDH2 Gene Mutation; Progressive Disease; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Drug: Ceralasertib; Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
Feeds
13354 items (13354 unread) in 74 feeds
Acinar Cell Carcinoma
(66 unread)
Acinic Cell Carcinoma
(48 unread)
Adenoid Cystic Carcinoma
(261 unread)
Adrenal Gland Cancer
(1125 unread)
Ampulla Of Vater
(174 unread)
Anal Cancer
(1482 unread)
Angiosarcoma
(433 unread)
Appendix Cancer
(154 unread)
Bile Duct Cancer
(1492 unread)
Brain and CNS
(1891 unread)
Carcinoid
(634 unread)
Endocrine/Neuroendocrine
(1797 unread)
Gall Bladder Cancer
(634 unread)
Hemangioendothelioma
(82 unread)
Hepatoblastoma
(212 unread)
Pancreas
(156 unread)
Phyllodes
(83 unread)
PMP and Mucinous Tumors
(109 unread)
Rhabdomyosarcoma
(455 unread)
Sarcoma
(2066 unread)
Trial - Cholangiocarcinoma (51 unread)
-
Olaparib and Ceralasertib in Treating Patients With IDH Mutant Cholangiocarcinoma or Solid Tumors
Posted: March 18th, 2019, 2:00pm GMT
-
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Posted: March 13th, 2019, 2:00pm GMT
Conditions: Solid Tumor; Colon Cancer; Cholangiocarcinoma; Bladder Cancer; Ovarian Cancer; Gastric Cancer; Palpable Subcutaneous Malignant Lesions
Interventions: Biological: TRK-950; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-FU; Drug: Gemcitabine; Drug: Cisplatin; Drug: Carboplatin; Biological: Ramucirumab; Drug: Paclitaxel; Biological: Nivolumab; Biological: Pembrolizumab; Drug: Imiquimod Cream
Sponsor: Toray Industries, Inc
Recruiting -
Toripalimab or Placebo as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Posted: March 8th, 2019, 3:00pm GMT
Condition: Epatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
Intervention: Biological: TORIPALIMAB INJECTION(JS001 )
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting -
Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images
Posted: February 25th, 2019, 3:00pm GMT
Conditions: Gallstone; Cholangitis; Cholangiocarcinoma; Pancreatitis; Pancreatic Ductal Adenocarcinoma
Intervention: Other: ultra-rapid acquisition of bile ducts images
Sponsor: IHU Strasbourg
Recruiting -
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
Posted: February 7th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention: Drug: M7824
Sponsors: EMD Serono Research & Development Institute, Inc.; Merck KGaA, Darmstadt, Germany
Not yet recruiting -
TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
Posted: February 4th, 2019, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Metastatic Castration Resistant Prostate Cancer; Renal Cell Carcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Squamous Cell Carcinoma of Head and Neck; Triple-Negative Breast Cancer; Urothelial Carcinoma; Cholangiocarcinoma; GastroEsophageal Cancer; Pancreatic Cancer; Sarcoma
Interventions: Drug: Part 1 TPST-1120; Drug: Part 2a TPST-1120 + nivolumab; Drug: Part 2b TPST-1120 + docetaxel; Drug: Part 2c TPST-1120 + cetuximab; Drug: Part 3 TPST-1120; Drug: Part 4a TPST-1120 + nivolumab; Drug: Part 4b TPST-1120 + docetaxel; Drug: Part 4c TPST-1120 + cetuximab
Sponsor: Tempest Therapeutics
Not yet recruiting -
Clinical Trial of Autologous Tcm Immunotherapy in ICC
Posted: January 29th, 2019, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Biological: autologous Tcm cellular immunotherapy
Sponsors: Newish Technology (Beijing) Co., Ltd.; Peking Union Medical College Hospital
Not yet recruiting -
A Phase 1 Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Posted: January 29th, 2019, 3:00pm GMT
Condition: HER2-expressing Cancers
Intervention: Drug: ZW49
Sponsor: Zymeworks Inc.
Recruiting -
Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer
Posted: January 28th, 2019, 3:00pm GMT
Conditions: Gastric Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Unresectable Esophageal Carcinoma; Unresectable Pancreatic Carcinoma
Intervention: Dietary Supplement: Zinc
Sponsor: Emory University
Not yet recruiting -
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Posted: January 14th, 2019, 3:00pm GMT
Conditions: Colon Cancer; Pancreatic Cancer; Cholangiocarcinoma; Mestatic Colon Carcinoma; Liver Metastasis
Interventions: Drug: MVT-5873; Procedure: pancreatectomy or hepatectomy
Sponsor: National Cancer Institute (NCI)
Not yet recruiting -
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Posted: January 11th, 2019, 3:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: Lenvatinib
Sponsor: Sun Yat-sen University
Recruiting -
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Posted: January 11th, 2019, 3:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Biliary Tract Neoplasms
Intervention: Biological: Tumor Infiltrating Lymphocytes (TIL)
Sponsor: Udai Kammula
Recruiting -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
Posted: December 20th, 2018, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases
Intervention: Drug: MIV-818
Sponsor: Medivir
Recruiting -
Phase 3 Study of BJG398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Posted: December 12th, 2018, 3:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Interventions: Drug: BGJ398; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: QED Therapeutics, Inc.
Recruiting -
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
Posted: November 8th, 2018, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gastric Cancer; Esophageal Cancer; Colorectal Cancer
Intervention: Drug: ZSP1241
Sponsor: Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Recruiting -
A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Posted: September 26th, 2018, 2:00pm GMT
Conditions: Cohort 1a and 1b: Glioma; Cohort 1a and 1b: Glioblastoma Multiforme; Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Solid Tumors With IDH1 Mutations
Interventions: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin
Sponsor: Forma Therapeutics, Inc.
Recruiting -
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)
Posted: September 3rd, 2018, 2:00pm GMT
Conditions: Unresectable Cholangiocarcinoma; Metastatic Cholangiocarcinoma
Interventions: Drug: Pemigatinib; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Incyte Corporation
Recruiting -
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
Posted: August 2nd, 2018, 2:00pm GMT
Condition: Gastrointestinal Cancer
Interventions: Other: Surgeon-palliative care team co management; Other: Surgeon team alone management
Sponsors: Stanford University; Patient-Centered Outcomes Research Institute
Recruiting -
Prospective Surveillance for Very Early Hepatocellular Carcinoma
Posted: July 17th, 2018, 2:00pm GMT
Condition: Carcinoma, Hepatocellular
Intervention:
Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting -
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Posted: July 9th, 2018, 2:00pm GMT
Conditions: Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel
Sponsors: Emory University; Celgene
Recruiting -
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Posted: March 2nd, 2018, 3:00pm GMT
Conditions: Cancer, Metastatic; Cancer; Cancer of Pancreas; Cancer of Liver; Cancer of Stomach; Cancer Liver; Cancer of Rectum; Cancer of Kidney; Cancer of Esophagus; Cancer of Cervix; Cancer of Colon; Cancer of Larynx; Cancer, Lung; Cancer, Breast; Cancer, Advanced; Cancer Prostate; Cancer of Neck; Cancer of Skin; Neuroendocrine Tumors; Carcinoma; Mismatch Repair Deficiency; BRCA Gene Rearrangement; Non Hodgkin Lymphoma; Leukemia; Non Small Cell Lung Cancer; Cholangiocarcinoma; Glioblastoma; Central Nervous System Tumor; Melanoma; Urothelial Carcinoma; Bladder Cancer; Ovarian Cancer; Endometrial Cancer; Testicular Cancer; Breast Cancer
Intervention: Other: Clinical Trial Matching
Sponsor: Massive Bio, Inc.
Recruiting -
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Posted: February 6th, 2018, 3:00pm GMT
Conditions: Breast Cancer; Colorectal Cancer; Cholangiocellular Carcinoma; Sarcoma; Desmoid Tumour; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant
Intervention: Drug: CB-103
Sponsor: Cellestia Biotech AG
Recruiting -
Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer
Posted: January 24th, 2018, 3:00pm GMT
Conditions: Liver Cancer; Liver Metastases
Intervention: Radiation: SBRT
Sponsor: Centre Oscar Lambret
Recruiting -
A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma
Posted: December 19th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Perihilar; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic
Intervention: Drug: ABC294640
Sponsor: RedHill Biopharma Limited
Recruiting -
Multiorgan Metabolic Imaging Response Assessment of Abemaciclib
Posted: November 13th, 2017, 3:00pm GMT
Conditions: Esophageal Adenocarcinoma; Esophagus SCC; Cholangiocarcinoma; Urothelial/Bladder Cancer, Nos; Endometrial Cancer
Intervention: Drug: Abemaciclib
Sponsors: Jules Bordet Institute; Eli Lilly and Company
Recruiting -
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Posted: November 6th, 2017, 3:00pm GMT
Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Other Solid Tumors; Diffuse Large B-cell Lymphoma (DLBCL); Mantle Cell Lymphoma; Indolent B-cell Lymphomas; Non-Hodgkin Lymphoma
Interventions: Drug: CDX-1140; Drug: CDX-301
Sponsor: Celldex Therapeutics
Recruiting -
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Posted: July 12th, 2017, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Melanoma; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Skin Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Intestinal Neoplasms; Thyroid Cancer; GIST; Malignant Peripheral Nerve Sheath Tumors; Breast Secretory Carcinoma; Uterine Neoplasms; Fibrosarcoma; Infantile Fibrosarcoma; Congenital Mesoblastic Nephroma; Central Nervous System Neoplasms
Intervention: Drug: LOXO-195
Sponsors: Loxo Oncology, Inc.; Bayer
Recruiting -
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Posted: June 7th, 2017, 2:00pm GMT
Conditions: Autoimmune Liver Disease; Autoimmune Hepatitis; Primary Sclerosing Cholangitis
Intervention:
Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Posted: May 9th, 2017, 2:00pm GMT
Conditions: Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Esophageal Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Solid Tumors
Intervention: Drug: INCB062079
Sponsor: Incyte Corporation
Recruiting -
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Posted: April 13th, 2017, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Cholangiocarcinoma; Bile Duct Cancer; Liver Cancer; Gallbladder Cancer
Interventions: Biological: Pembrolizumab (MK-3475); Drug: Oxaliplatin; Drug: Capecitabine
Sponsor: National Cancer Institute (NCI)
Recruiting -
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Posted: March 7th, 2017, 3:00pm GMT
Condition: Advanced Solid Tumors Cancer
Interventions: Drug: ABBV-368; Drug: ABBV-181
Sponsor: AbbVie
Recruiting -
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
Posted: February 7th, 2017, 3:00pm GMT
Conditions: Adenocarcinoma Metastatic; Biliary Tract Cancer; Adenocarcinoma of the Biliary Tract; Adenocarinoma Locally Advanced; Non-Resectable Hepatocellular Carcinoma; Intrahepatic Bile Duct Carcinoma; Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A); Drug: Arm Cisplatin + Gemcitabine (Arm B)
Sponsors: AIO-Studien-gGmbH; Takeda (Shire, Baxalta); Institut für Klinisch-Onkologische Forschung (IKF) am Krankenhaus Nordwest GmbH; Shire
Recruiting -
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
Posted: February 6th, 2017, 3:00pm GMT
Conditions: Cholangiocarcinoma Non-resectable; Cholangiocarcinoma Metastatic; Cholangiocarcinoma of the Gallbladder; Cholangiocarcinoma Advanced
Interventions: Drug: nal-IRI; Drug: 5-FU; Drug: leucovorin
Sponsors: AIO-Studien-gGmbH; Shire
Recruiting -
A Study of ABBV-181 in Participants With Advanced Solid Tumors
Posted: December 22nd, 2016, 3:00pm GMT
Condition: Advanced Solid Tumors
Interventions: Drug: Rovalpituzumab Tesirine; Drug: ABBV-181
Sponsor: AbbVie
Recruiting -
A Study of TRK-950 in Patients With Advanced Solid Tumors
Posted: December 13th, 2016, 3:00pm GMT
Conditions: Locally Advanced or Metastatic Solid Carcinomas; Colon Cancer; Cholangiocarcinoma
Intervention: Biological: TRK-950
Sponsor: Toray Industries, Inc
Recruiting -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
Posted: October 5th, 2016, 2:00pm GMT
Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting -
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Posted: July 15th, 2016, 2:00pm GMT
Conditions: Advanced Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Hepatocellular Carcinoma; Liver Cancer; Liver Neoplasms; Hepatic Cancer; Hepatic Carcinoma; Cholangiocarcinoma; Bile Duct Cancer
Intervention: Drug: H3B-6527
Sponsors: H3 Biomedicine Inc.; Eisai Inc.
Recruiting -
Quality of Life in Patients With Primary Sclerosing Cholangitis
Posted: March 18th, 2016, 2:00pm GMT
Condition: Primary Sclerosing Cholangitis
Intervention: Other: quality of life survey
Sponsor: Duke University
Recruiting -
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho
Posted: March 4th, 2016, 3:00pm GMT
Condition: Neoplasm
Intervention: Drug: Erdafitinib
Sponsor: Janssen Research & Development, LLC
Recruiting -
A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction
Posted: January 20th, 2016, 3:00pm GMT
Conditions: Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; HCC; AOV Cancer
Interventions: Procedure: side by side; Procedure: stent in stent
Sponsor: Yonsei University
Recruiting -
Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study
Posted: January 5th, 2016, 3:00pm GMT
Condition: Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
Interventions: Device: Radiofrequency ablation with stenting; Device: stenting
Sponsor: Yonsei University
Recruiting -
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Posted: December 16th, 2015, 3:00pm GMT
Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting -
Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Posted: October 15th, 2015, 2:00pm GMT
Conditions: Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Sarcoma; Colorectal Neoplasms; Salivary Gland Neoplasms; Biliary Tract Neoplasms; Brain Neoplasm, Primary; Carcinoma, Ductal, Breast; Melanoma; Solid Tumors; Glioblastoma; Bile Duct Neoplasms; Astrocytoma; Head and Neck Squamous Cell Carcinoma; Pontine Glioma; Pancreatic Neoplasms; Ovarian Neoplasms; Carcinoma, Renal Cell; Cholangiocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas
Intervention: Drug: Larotrectinib LOXO-101
Sponsors: Bayer; Loxo Oncology, Inc.
Recruiting -
OLAParib COmbinations
Posted: October 15th, 2015, 2:00pm GMT
Condition: Cancer
Interventions: Drug: AZD2281; Drug: AZD5363; Drug: AZD1775; Drug: AZD6738
Sponsors: Joseph Paul Eder; Dana-Farber Cancer Institute; Vanderbilt-Ingram Cancer Center; The Cleveland Clinic
Recruiting -
Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)
Posted: August 24th, 2015, 2:00pm GMT
Condition: Pancreatic Neoplasms
Intervention: Other: blood and bile
Sponsor: Florida Hospital
Recruiting -
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
Posted: May 27th, 2015, 2:00pm GMT
Condition: Solid Tumor
Intervention: Biological: FF21101
Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.
Recruiting -
Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)
Posted: March 19th, 2015, 2:00pm GMT
Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
Interventions: Drug: Pemigatinib; Drug: Gemcitabine + Cisplatin; Drug: Pembrolizumab; Drug: Docetaxel; Drug: Trastuzumab; Drug: INCMGA00012
Sponsor: Incyte Corporation
Recruiting -
Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L
Posted: September 5th, 2014, 2:00pm GMT
Conditions: Hepatocellular Carcinoma; HCC; Liver Cancer
Interventions: Biological: hepcortespenlisimut-L; Biological: Placebo
Sponsor: Immunitor LLC
Recruiting -
Treatment for Bile Duct Cancer in the Liver
Posted: June 19th, 2014, 2:00pm GMT
Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
Sponsor: Chinese University of Hong Kong
Recruiting -
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Posted: May 30th, 2014, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation
Intervention: Drug: BGJ398 (infigratinib)
Sponsor: QED Therapeutics, Inc.
Recruiting -
International Registry on Cholangiocarcinoma Treatment
Posted: August 12th, 2013, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: Doxorubicin
Sponsor: International Group of Endovascular Oncology
Recruiting